Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mugdha Agrawal

Rheumatology Voorhees, NJ Medical Doctor

NPI 1144595414 CMS profile 1317724

2301 E Evesham Rd Ste 115, Voorhees, NJ 08043

Open in the dashboard

General payments

$6,981

369 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$44,694 paid to institutions, not to them · program years 2021–2024

Through program year 2025, Mugdha Agrawal of Voorhees, NJ is reported in the CMS Open Payments database as having received $6,981 across 369 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $44,694 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 66th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $724 54
2024 General $920 34
2023 General $108 7
2022 General $321 24
2021 General $462 26
2020 General $1,093 54
2019 General $3,354 170

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mugdha Agrawal
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Mugdha Agrawal were reported at $724. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Mugdha Agrawal Rheumatology median Middle half National median
2019 $3,354 $744 $153–$2,687 $163
2020 $1,093 $462 $98–$2,027 $114
2021 $462 $531 $101–$2,153 $132
2022 $321 $627 $125–$2,303 $149
2023 $108 $741 $145–$2,524 $160
2024 $920 $830 $166–$2,660 $164
2025 $724 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,395 90 payments
  2. Amgen Inc. $1,023 56 payments
  3. Janssen Biotech, Inc. $641 23 payments
  4. Pfizer Inc. $600 29 payments
  5. Novartis Pharmaceuticals Corporation $436 21 payments
  6. Lilly USA, LLC $375 23 payments
  7. E.R. Squibb & Sons, L.L.C. $362 29 payments
  8. Celgene Corporation $355 11 payments
  9. Genentech USA, Inc. $253 12 payments
  10. Horizon Therapeutics plc $235 13 payments
  11. Other $1,306 62 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,736 364 payments
  2. Education $246 5 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $721 52 payments
  2. Prolia $610 39 payments
  3. XELJANZ $537 26 payments
  4. TREMFYA $433 12 payments
  5. EVENITY $422 27 payments
  6. HUMIRA $393 26 payments
  7. TALTZ $375 23 payments
  8. COSENTYX $367 18 payments
  9. ORENCIA $359 28 payments
  10. SIMPONI ARIA $326 11 payments
  11. Other $3,601 175 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

935

Median for Rheumatology: 1,511

Drug cost

$198,278

Median for Rheumatology: $1,139,948

Branded share of claims

24%

Median for Rheumatology: 28.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cosentyx Sensoready (2 Pens) Secukinumab Brand 14 $99,359
Humira(Cf) Adalimumab Brand 12 $80,048
Methotrexate Methotrexate Sodium Brand 182 $5,245
Hydroxychloroquine Sulfate Generic 81 $4,239
Leflunomide Generic 54 $2,576
Colchicine Generic 11 $968
Sulfasalazine Generic 33 $936
Prednisone Generic 167 $868
Tramadol Hcl Generic 73 $587
Allopurinol Generic 47 $576

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,224 Part D prescribers listed as Rheumatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 63 billing codes

Paid by Medicare

$1,542,615

Of which drugs: $1,374,648

Medicare patients

741

Average age 75

Services billed

128,008

592 women, 149 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Osteoporosis 53%
Ischemic heart disease 30%
Depression 22%
Chronic kidney disease 21%
Diabetes 20%
COPD 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0129 Office 37 5,725 $194,286
Injection, denosumab, 1 mg J0897 Office 111 8,460 $173,964
Injection, tocilizumab, 1 mg J3262 Office 29 30,920 $140,466
Injection, inclisiran, 1 mg J1306 Office 44 13,916 $129,977
Injection, romosozumab-aqqg, 1 mg J3111 Office 33 11,340 $98,165
Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0717 Office 40 26,600 $95,850
Injection, infliximab, excludes biosimilar, 10 mg J1745 Office 40 3,610 $86,847
Injection, golimumab, 1 mg, for intravenous use J1602 Office 39 9,650 $86,340
Injection, zoledronic acid, 1 mg J3489 Office 40 200 $968
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 64 557 $415

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $216
$216 — —
KRYSTEXXA
  • Amgen Inc. $143
$143 — —
RINVOQ
  • AbbVie, Inc. $106
$106 — —
SIMPONI ARIA
  • Janssen Biotech, Inc. $70
$70 — 9,650
ORENCIA
  • E.R. Squibb & Sons, L.L.C. $53
$53 — 5,725

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

369 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record